ABG Innovation Capital Partners III GP Ltd Long-Term Concentrated

CIK: 0001845297 · Show all filings

Period: Q4 2021 (← Previous) (Next →)

Filing Date: Feb 14, 2022

Total Value ($000): $1,729 (100.0% shares, 0.0% debt)

Holdings (6)

WHWK AADI BIOSCIENCES INC 37.2%

Value ($000) $644 Shares 26,666 Est. Cost $30.48 Unrealized -17.6%

— SYNLOGIC INC 28.8%

Value ($000) $498 Shares 205,906 Est. Cost $2.16 Unrealized —

GNCAQ GENOCEA BIOSCIENCES INC 25.2%

Value ($000) $435 Shares 375,000 Est. Cost $2.28 Unrealized -34.6%

LUNG PULMONX CORP 5.4%

Value ($000) $93 Shares 2,901 Est. Cost $48.97 Unrealized -25.4%

— IDERA PHARMACEUTICALS INC 1.9%

Value ($000) $32 Shares 56,250 Est. Cost $3.66 Unrealized —

— NABRIVA THERAPEUTICS PLC 1.6%

Value ($000) $27 Shares 45,849 Est. Cost $2.42 Unrealized —

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
WHWK	AADI BIOSCIENCES INC	26,666	$644	37.2%	$30.48	-17.6%	COM	00032Q104
—	SYNLOGIC INC	205,906	$498	28.8%	$2.16	—	COM	87166L100
GNCAQ	GENOCEA BIOSCIENCES INC	375,000	$435	25.2%	$2.28	-34.6%	COM NEW	372427401
LUNG	PULMONX CORP	2,901	$93	5.4%	$48.97	-25.4%	COM	745848101
—	IDERA PHARMACEUTICALS INC	56,250	$32	1.9%	$3.66	—	COM PAR	45168K405
—	NABRIVA THERAPEUTICS PLC	45,849	$27	1.6%	$2.42	—	SHS	G63637113